Home  »  Business   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Citius Pharmaceuticals Inc. (CTXR)

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) went down by -15.00% from its latest closing price compared to the recent 1-year high of $2.01. The company’s stock price has collected 5.31% of gains in the last five trading sessions.

Is It Worth Investing in Citius Pharmaceuticals Inc. (NASDAQ :CTXR) Right Now?

Plus, the 36-month beta value for CTXR is at 1.27. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Citius Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $7.00, which is $5.81 above the current price. CTXR currently public float of 133.82M and currently shorts hold a 8.19% ratio of that float. Today, the average trading volume of CTXR was 702.92K shares.

CTXR’s Market Performance

CTXR stocks went up by 5.31% for the week, with a monthly jump of 15.53% and a quarterly performance of 13.33%, while its annual performance rate touched -19.05%. The volatility ratio for the week stands at 15.13% while the volatility levels for the past 30 days are set at 10.70% for Citius Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 19.00% for CTXR stocks with a simple moving average of 9.94% for the last 200 days.

Analysts’ Opinion of CTXR

Many brokerage firms have already submitted their reports for CTXR stocks, with Maxim Group repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to Maxim Group is $4 based on the research report published on November 30th of the previous year 2021.

CTXR Trading at 10.60% from the 50-Day Moving Average

After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.80% of loss for the given period.

Volatility was left at 10.70%, however, over the last 30 days, the volatility rate increased by 15.13%, as shares surge +16.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.33% upper at present.

During the last 5 trading sessions, CTXR rose by +5.31%, which changed the moving average for the period of 200-days by -30.41% in comparison to the 20-day moving average, which settled at $1.0085. In addition, Citius Pharmaceuticals Inc. saw 50.63% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for CTXR

Equity return is now at value -29.60, with -26.90 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.84.

Is SSR Mining Inc. (SSRM) a Keeper?

SSR Mining Inc. (NASDAQ:SSRM) went down by -3.03% from its latest closing price compared to the recent 1-year high of $24.58. The company’s stock price